LLY

1,141.85

+4.79%↑

JNJ

231.01

-0.17%↓

ABBV

218.68

+2.43%↑

UNH

386.88

+1.29%↑

MRK

120.62

-0.54%↓

LLY

1,141.85

+4.79%↑

JNJ

231.01

-0.17%↓

ABBV

218.68

+2.43%↑

UNH

386.88

+1.29%↑

MRK

120.62

-0.54%↓

LLY

1,141.85

+4.79%↑

JNJ

231.01

-0.17%↓

ABBV

218.68

+2.43%↑

UNH

386.88

+1.29%↑

MRK

120.62

-0.54%↓

LLY

1,141.85

+4.79%↑

JNJ

231.01

-0.17%↓

ABBV

218.68

+2.43%↑

UNH

386.88

+1.29%↑

MRK

120.62

-0.54%↓

LLY

1,141.85

+4.79%↑

JNJ

231.01

-0.17%↓

ABBV

218.68

+2.43%↑

UNH

386.88

+1.29%↑

MRK

120.62

-0.54%↓

Home・Aktien・Guardant Health Inc

Guardant Health Inc

Open

BrancheGesundheitswesen

129.14 5.09

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

123.34

Max

130.77

Schlüsselkennzahlen
By Trading Economics
Einkommen	16M -112M
Verkäufe	20M 302M
EPS	-0.45
Gewinnspanne	-37.152
Angestellte	2,490
EBITDA	18M -101M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+8.04% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	29. Juli 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	3.7B 16B
Vorheriger Eröffnungskurs	124.05
Vorheriger Schlusskurs	129.14

Nachrichtenstimmung

By Acuity

100%

328 / 344 Ranking in Healthcare

Guardant Health Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Guardant Health Inc Prognose

Kursziel

By TipRanks

8.04% Vorteil

12-Monats-Prognose

Durchschnitt 129.48 USD 8.04%

Hoch 160 USD

Tief 95 USD

Basierend auf 15 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Guardant Health Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

15 ratings

Buy

Halten

Sell

Basierend auf 15 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Guardant Health Inc – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.